JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M108023200 on March 19, 2002

J. Biol. Chem., Vol. 277, Issue 22, 19546-19553, May 31, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
277/22/19546    most recent
M108023200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cai, Z.
Right arrow Articles by Sheppard, D. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cai, Z.
Right arrow Articles by Sheppard, D. N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Phloxine B Interacts with the Cystic Fibrosis Transmembrane Conductance Regulator at Multiple Sites to Modulate Channel Activity*,

Zhiwei Cai and David N. SheppardDagger

From the Department of Physiology, University of Bristol, School of Medical Sciences, University Walk, Bristol BS8 1TD and the Medical Genetics Section, University of Edinburgh, Molecular Medicine Centre, Western General Hospital, Edinburgh EH4 2XU, United Kingdom

Received for publication, August 20, 2001, and in revised form, February 19, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The fluorescein derivative phloxine B is a potent modulator of the cystic fibrosis transmembrane conductance regulator (CFTR). Low micromolar concentrations of phloxine B stimulate CFTR Cl- currents, whereas higher concentrations of the drug inhibit CFTR. In this study, we investigated the mechanism of action of phloxine B. Phloxine B (1 µM) stimulated wild-type CFTR and the most common cystic fibrosis mutation, Delta F508, by increasing the open probability of phosphorylated CFTR Cl- channels. At each concentration of ATP tested, the drug slowed the rate of channel closure without altering the opening rate. Based on the effects of fluorescein derivatives on transport ATPases, these data suggest that phloxine B might stimulate CFTR by binding to the ATP-binding site of the second nucleotide-binding domain (NBD2) to slow the dissociation of ATP from NBD1. Channel block by phloxine B (40 µM) was voltage-dependent, enhanced when external Cl- concentration was reduced and unaffected by ATP (5 mM), suggesting that phloxine B inhibits CFTR by occluding the pore. We conclude that phloxine B interacts directly with CFTR at multiple sites to modulate channel activity. It or related agents might be of value in the development of new treatments for diseases caused by the malfunction of CFTR.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The cystic fibrosis transmembrane conductance regulator (CFTR1 (1)) is a novel member of the ATP-binding cassette (ABC) transporter family that forms a Cl- channel with complex regulation (2, 3). It is predominantly expressed in epithelia, where it provides a pathway for the movement of Cl- ions across the apical membrane and regulates the rate of transepithelial salt and water transport (4). Dysfunction of CFTR is associated with a wide spectrum of disease. The genetic disease cystic fibrosis (CF) is caused by loss of function of the CFTR Cl- channel (4). CF affects ~1 in 2500 live births and is the most common fatal autosomal recessive disease to affect Caucasian populations (4). Other diseases, such as autosomal dominant polycystic kidney disease (ADPKD) and secretory diarrhea, likely involve increased activity of the CFTR Cl- channel (5, 6). ADPKD affects more than 1 in 1000 live births and is the most common single gene defect associated with the loss of kidney function (5). Secretory diarrhea annually kills millions of infants in Africa, Asia, and Latin America (7). The prevalence of these diseases suggests that modulators of the CFTR Cl- channel have significant therapeutic potential.

Several pharmacological strategies to manipulate the activity of the CFTR Cl- channel have been identified. Some agents promote channel opening by modulating the activity of the protein kinases and phosphatases that regulate CFTR (2, 8). For example, the phenylimidazothiazole drug bromotetramisole inhibits the protein phosphatases that dephosphorylate CFTR (9). In contrast, other agents interact directly with CFTR to enhance channel activity (8, 10). The binding of the flavonoid genistein to the second nucleotide-binding domain (NBD2) prolongs dramatically the duration of channel openings (11-14), whereas cyclophilin A, a cis-trans peptidyl-prolyl isomerase, interacts with the R (regulatory) domain to stimulate greatly the activity of CFTR (15).

New inhibitors of the CFTR Cl- channel have emerged from studies of agents that interact with other ABC transporters, including the sulfonylurea receptor (SUR) and multidrug-resistance associated proteins (MRPs, Ref. 16). SUR is the regulatory subunit of ATP-sensitive K+ channels (KATP channels (17)). It binds sulfonylureas, a class of hypoglycemia-inducing drugs used to treat non-insulin-dependent diabetes mellitus, to inhibit K+ flow through the pore-forming subunit of KATP channels (Kir6.2 (17)). Like their effects on KATP channels, the sulfonylureas glibenclamide and tolbutamide and the non-sulfonylurea hypoglycemic agents meglitinide and mitiglinde inhibit the CFTR Cl- channel (18-20). MRPs hydrolyze ATP to export a wide range of large anions from cells (21). Linsdell and Hanrahan (22) demonstrated that two substrates of MRPs, taurolithocholate-3-sulfate and beta -estradiol 17-(beta -D-glucuronide), inhibit the CFTR Cl- channel. The data indicate that hypoglycemia-inducing drugs and substrates of MRPs block the CFTR Cl- channel by occluding the intracellular end of the CFTR pore (19, 22).

In the search for new modulators of CFTR, we tested the effect on the CFTR Cl- channel of fluorescein derivatives, a group of drugs used to investigate the function of transport ATPases and KATP channels (23-26). Like its effect on KATP channels (25), the fluorescein derivative phloxine B both stimulated and inhibited channel activity (27, present study). To understand better the mechanism of action of phloxine B, we studied CFTR Cl- channels in excised inside-out membrane patches from cells expressing human CFTR.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells and Cell Culture-- For these studies, we used mouse mammary epithelial cells (C127 cells) stably expressing either wild-type human CFTR or Delta F508, the most common CF-associated mutation (28). C127 cells expressing wild-type CFTR were cultured as previously described (19). C127 cells expressing Delta F508 CFTR were cultured at 28 °C to overcome the processing defect of this mutation and promote its delivery to the cell membrane (29). Cells were seeded onto glass coverslips and used within either 2 days (wild-type CFTR) or 1 week (Delta F508 CFTR).

Electrophysiology-- CFTR Cl- channels were recorded in excised inside-out membrane patches using an Axopatch 200A patch-clamp amplifier (Axon Instruments Inc., Union City, CA) and pClamp data acquisition and analysis software (version 6.03, Axon Instruments Inc.) as previously described (19, 30). The established sign convention was used throughout; currents produced by positive charge moving from intra- to extracellular solutions (anions moving in the opposite direction) are shown as positive currents.

The pipette (extracellular) solution contained (in millimolar): 140 N-methyl-D-glucamine (NMDG), 140 aspartic acid, 5 CaCl2, 2 MgSO4, and 10 N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), pH 7.3, with Tris ([Cl-], 10 mM). The bath (intracellular) solution contained (millimolar): 140 NMDG, 3 MgCl2, 1 CsEGTA, and 10 TES, pH 7.3, with HCl ([Cl-], 147 mM, free [Ca2+], <10-8 M) and was maintained at 37 °C.

After excision of inside-out membrane patches, CFTR Cl- channels were activated by the addition of the catalytic subunit of protein kinase A (PKA, 75 nM) and ATP (1 mM) to the intracellular solution within 5 min of patch excision. Unless otherwise specified, the ATP concentration was reduced to 0.3 mM before the addition of phloxine B to the intracellular solution as previously described (31); PKA was added to all intracellular solutions. Membrane patches were voltage-clamped at -50 mV.

In this study, we used membrane patches containing large numbers of active channels for time-course studies and voltage ramp protocols and membrane patches containing five or less active channels for single-channel studies. The number of channels in a membrane patch was determined from the maximum number of simultaneous channel openings observed during the course of an experiment as described previously (32). Because the effects of phloxine B on CFTR Cl- channels were only partially reversible (Fig. 7C), specific interventions were not bracketed by control periods. However, we have previously shown that in the continuous presence of PKA and ATP rundown of CFTR Cl- channels in excised membrane patches from C127 cells is minimal (19).

To investigate whether phloxine B inhibition of CFTR was voltage-dependent and enhanced when the external Cl- concentration was reduced, we used voltage ramp protocols to acquire macroscopic current-voltage (I-V) relationships as previously described (31). Basal currents recorded before the addition of PKA and ATP were subtracted from those recorded in the absence and presence of phloxine B to determine the effect of phloxine B on CFTR Cl- currents.

CFTR Cl- currents were initially recorded on digital audiotape using a digital tape recorder (Biologic Scientific Instruments, model DTR-1204, Intracel Ltd., Royston, UK) at a bandwidth of 10 kHz. On playback, records were filtered with an eight-pole Bessel filter (Frequency Devices, model 902LPF2, Scensys Ltd., Aylesbury, UK) at a corner frequency of 500 Hz and acquired using a Digidata 1200 interface (Axon Instruments, Inc.) and pClamp at sampling rates of either 2.5 kHz (time-course studies) or 5 kHz (single-channel studies). For the purpose of illustration, single-channel records were filtered at 500 Hz and digitized at 1 kHz.

In time-course studies, each data point is the average current for a 4-s period with data points collected continuously; no data were collected while solutions were changed. Average current (I) for a specific intervention was determined as the average of all the data points collected during the intervention. The relationship between drug concentration and CFTR inhibition was fitted to the Hill equation,
I<SUB><UP>Drug</UP></SUB>/I<SUB><UP>Control</UP></SUB>=1/<FENCE>1+([<UP>Drug</UP>]/K<SUB>i</SUB>)<SUP>n</SUP></FENCE> (Eq. 1)
where [Drug] is the concentration of drug, IDrug/IControl is the fractional current at the indicated drug concentration relative to that in the same solution in the absence of added drug, Ki is the drug concentration causing half-maximal inhibition, and n is the slope factor (Hill coefficient). Mean data were fitted to a linear form of Equation 1 using linear least-squares regression to yield Ki and n values.

To measure single-channel current amplitude (i), Gaussian distributions were fit to current amplitude histograms. For open probability (Po) and burst analyses, lists of open- and closed-times were created and analyzed as previously described (31). Burst analysis was performed as described by Carson et al. (33), using a tc (the time that separates interburst closures from intraburst closures) of 15 ms. Mean interburst interval (Tc) was calculated using the equation,
P<SUB><UP>o</UP></SUB>=T<SUB><UP>b</UP></SUB>/(T<SUB><UP>b</UP></SUB>+T<SUB><UP>c</UP></SUB>) (Eq. 2)
where Tb = (mean burst duration) × (open probability within a burst). Mean burst duration and open probability within a burst were determined directly from experimental data; Po was calculated from open and closed times. Only membrane patches that contained a single active channel were used for burst analysis.

To perform maximum likelihood analysis and develop kinetic models to quantify the interaction of phloxine B with CFTR, we used the QuB software suite (www.qub.buffalo.edu). In brief, digitized current records generated by pClamp software were imported with no further filtering and baseline corrected (program PRE). Using a recursive Viterbi algorithm (program SKM), idealized currents were produced. Finally, rate constants for kinetic models were calculated from the idealized current dwell time sequence using a maximum likelihood approach (program MIL). For consistency with analyses using pClamp software, transitions of <1 ms were excluded. With the exception of the ADP data (Fig. 5 and supplementary information), only membrane patches that contained a single active channel were used for maximum likelihood analysis and kinetic modeling.

Reagents-- PKA was purchased from Promega Corp. (Southampton, UK). ATP (disodium salt), glibenclamide, phloxine B (2',4',5',7'-tetrabromo-4,5,6,7-tetrachlorofluorescein, Fig. 1A), and TES were obtained from the Sigma-Aldrich Company Ltd. (Gillingham, UK). All other chemicals were of reagent grade.

Stock solutions of phloxine B were prepared in Me2SO and stored at -20 °C. Immediately before use, stock solutions were diluted to achieve final concentrations. Me2SO did not affect the activity of CFTR (19).

Statistics-- Results are expressed as means ± S.E. of n observations. To compare sets of data, we used Student's t test. Differences were considered statistically significant when p < 0.05.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phloxine B Stimulates and Inhibits the Activity of CFTR-- To examine the effect of the fluorescein derivative phloxine B on the activity of CFTR, we studied CFTR Cl- currents in excised inside-out membrane patches from C127 cells expressing wild-type human CFTR. In the absence of either ATP (n = 4) or PKA (n = 4), phloxine B was without effect on CFTR Cl- channels (data not shown). However, in the presence of both PKA (75 nM) and ATP (0.3 mM), addition of phloxine B to the intracellular solution altered channel activity (Fig. 1, B and C). Phloxine B (0.1-5 µM) stimulated CFTR Cl- current whereas, phloxine B (20-50 µM) inhibited channel activity. The inset of Fig. 1C shows the fit of the Hill equation to the relationship between phloxine B concentration and current inhibition (Ki = 17 µM; n = 2; correlation coefficient, r2 = 0.943 at -50 mV). These data suggest that phloxine B is a potent modulator of the CFTR Cl- channel: it stimulates CFTR with greater efficacy than genistein, and it inhibits channel activity with equipotency to glibenclamide (13, 19). The Hill plot also suggests that phloxine B might inhibit CFTR by binding at two or more sites that interact co-operatively. Modulation of CFTR by phloxine B was partially reversible (see Fig. 7C, below).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Phloxine B modulates the activity of CFTR. A, chemical structure of phloxine B. The anionic form is shown. B, time course of CFTR Cl- current in an excised inside-out membrane patch. ATP (0.3 mM), PKA (75 nM), and phloxine B (Phlx B, 5-50 µM) were present in the intracellular solution during the times indicated by the bars. Unless otherwise indicated, in this and subsequent figures, voltage was -50 mV and there was a Cl- concentration gradient across the membrane (internal [Cl-] = 147 mM; external [Cl-] = 10 mM). For the purpose of illustration, the time course has been inverted so that upward deflections represent inward currents. C, effect of phloxine B concentration on CFTR Cl- currents. Data are means ± S.E. (n = 4-7). Values above the dotted line indicate stimulation of CFTR, whereas values below the line indicate inhibition. Other details are as in B. The inset shows a Hill plot of phloxine B inhibition of CFTR. The continuous line is the fit of a first-order regression to the data.

Mechanism of Phloxine B Stimulation of CFTR-- In principle, phloxine B might stimulate CFTR Cl- currents in one of three ways: first, by increasing the number of active channels; second, by enhancing current flow through open channels; third, by increasing Po. To discriminate between these different possibilities, we investigated the effect of phloxine B (1 µM) on the single-channel activity of CFTR (Fig. 2). Visual inspection of single-channel records suggests that phloxine B (1 µM) did not stimulate CFTR by enhancing the number of active channels present in a membrane patch (n = 15, Fig. 2A). Similarly, phloxine B (1 µM) did not stimulate CFTR by increasing the amount of current flowing through an open channel. On the contrary, the drug produced a small, but significant (p < 0.05), reduction in i (Fig. 2B). Instead, phloxine B (1 µM) caused a large increase in Po (p < 0.0001; Fig. 2C).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 2.   Phloxine B (1 µM) stimulates the single-channel activity of CFTR. A, representative recordings show the effect of phloxine B (1 µM) on the activity of a single CFTR Cl- channel in an excised inside-out membrane patch. ATP (0.3 mM) and PKA (75 nM) were continuously present in the intracellular solution. Dashed lines indicate the closed channel state and downward deflections correspond to channel openings. B and C, effect of phloxine B (1 µM) on i and Po, respectively. Columns and error bars indicate means + S.E. (n = 15). The asterisks indicate values that are significantly different from the control value (p < 0.01); other details are as in A.

To determine how phloxine B (1 µM) increased Po, we investigated its effects on the gating kinetics of phosphorylated CFTR Cl- channels using membrane patches that contained only a single active channel. Using maximum likelihood analysis, Winter et al. (34) demonstrated that the simplest model to describe the gating kinetics of single phosphorylated wild-type CFTR Cl- channels is a linear three-state model (Fig. 3A). In this model, C1 represents the long duration closed state separating bursts of channel activity and C2 left-right-arrow O represents the bursting state in which channel openings (O) are interrupted by brief flickery closures (C2). Transitions between the three states are described by the rate constants beta 1, beta 2, alpha 1, and alpha 2. Winter et al. (34) demonstrated that intracellular ATP regulates CFTR at the transition between C1 and C2: as the ATP concentration increases, beta 1 increases. In contrast, the other transitions were not altered significantly by ATP (34). Similar analyses of our data support this model of ATP-dependent regulation of CFTR channel gating (see supplementary material).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of phloxine B (1 µM) on single-channel kinetics. A, a linear three-state model which describes the gating behavior of phosphorylated wild-type CFTR Cl- channels (34). States C1, C2, and O represent two closed states and one open state, respectively, while beta 1, beta 2, alpha 1, and alpha 2 represent the rate constants describing transitions between the open and closed states. B, effect of phloxine B (1 µM) on the rate constants determined by the maximum likelihood fit to the model shown in A. Data are from six single-channel patches. The asterisks indicate values that are significantly different from the control value (p < 0.01); other details are as in Fig. 2A.

Fig. 3B summarizes the effect of phloxine B (1 µM) on the rate constants. The major effect of phloxine B (1 µM) was to decrease alpha 1 to about 40% of the control value. The drug also increased beta 2 but did not change either beta 1 or alpha 2. The decrease in alpha 1 delays the exit from the bursting state to the long-lived closed state and, hence, increases burst duration. The increase in beta 2, the transition rate between the short-lived closed state and the open state, further increases the duration of bursts. These changes explain the observed increase in Po caused by phloxine B (1 µM, Fig. 2C).

Effect of ATP and ADP on Phloxine B Stimulation of CFTR-- The effect of phloxine B (1 µM) on channel gating resembles that of adenosine 5'-(beta ,gamma -imino)triphosphate (AMP-PNP) and genistein, two activators of the CFTR Cl- channel. Previous work suggests that these agents interact directly with NBD2, which regulates channel closure (11-14, 35). Based on these data and the observation that fluorescein derivatives prevent the hydrolysis of ATP by transport ATPases (23, 24), we speculated that phloxine B might compete with ATP for a common binding site on NBD2. To test this hypothesis, we examined the effect of ATP concentration on phloxine B (1 µM) stimulation of CFTR Cl- channels. Fig. 4 (A and B) shows that, as the ATP concentration increased, CFTR activity in both the absence and presence of phloxine B (1 µM) increased. With the exception of ATP (3 mM), at each concentration of ATP tested, Po values in the presence of phloxine B (1 µM) were significantly greater than those recorded in the absence of the drug (p < 0.05; Fig. 4B). In both the absence and presence of phloxine B (1 µM), mean data were best fitted by a Michaelis-Menten function (control: Km = 197 µM, maximum Po (Po max) = 0.59, r2 = 0.963; phloxine B: Km = 33 µM, Po max = 0.73; r2 = 0.983). These data suggest that phloxine B (1 µM) increases the affinity of CFTR for ATP. They also raise the possibility that phloxine B might not compete with ATP for a common binding site.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 4.   Phloxine B (1 µM) enhances ATP-dependent stimulation of CFTR. A, representative recordings show the effect of phloxine B (1 µM) on the activity of a single CFTR Cl- channel in the presence of different ATP concentrations. B, relationship between ATP concentration and Po in the absence (filled circles) and presence (open circles) of phloxine B (1 µM). Symbols and error bars are means ± S.E. (n = 6-12, except 3 mM ATP where n = 3) of paired data at each dose. Continuous lines are Michaelis-Menten fits to the mean data. C and D, relationship between ATP concentration and mean burst duration and interburst interval, respectively, in the absence (filled circles) and presence (open circles) of phloxine B (1 µM). Symbols and error bars are means ± S.E. (n = 3-7). Other details are as in Fig. 2A.

To quantify the effect of phloxine B (1 µM) on channel gating in the presence of different concentrations of ATP, we performed an analysis of bursts using a burst delimiter (tc) of 15 ms.2 Under control conditions, both interburst interval and burst duration exhibited ATP dependence. Interburst interval was highly ATP-dependent, decreasing 11-fold between 0.03 and 5 mM ATP (Fig. 4D). In contrast, burst duration was weakly ATP-dependent at low ATP concentrations, increasing 1.4-fold between 0.03 and 1 mM ATP, but ATP-independent at higher ATP concentrations (Fig. 4C). Phloxine B (1 µM) was without effect on the ATP dependence of the interburst interval (Fig. 4D). However, the drug caused a marked increase in burst duration at each concentration of ATP tested (Fig. 4C). These data correlate well with the results of maximum likelihood analysis of phloxine B (1 µM) stimulation of CFTR (Fig. 3 and supplementary material).

Winter et al. (34) demonstrated that ADP inhibits CFTR by slowing dramatically the rate of channel opening. To test the effect of phloxine B (1 µM) on ADP inhibition of CFTR, we first added ADP (0.3 mM) and then phloxine B (1 µM) to the intracellular solution in the continuous presence of ATP (0.3 mM) and PKA (75 nM, Fig. 5). Fig. 5 (A and B) shows that phloxine B (1 µM) stimulated CFTR Cl- channels inhibited by ADP. To understand better this effect, we studied the gating kinetics of CFTR using the C1 left-right-arrow C2 left-right-arrow O model (Fig. 5, C and D). The major effect of ADP (0.3 mM) was to decrease beta 1 to about 40% of the control value (Fig. 5D). In contrast, in the presence of ADP (0.3 mM) and phloxine B (1 µM), beta 1 and alpha 1 were decreased to about 30% of the control values, beta 2 was increased to about 140% of the control value, and alpha 2 was unchanged (Fig. 5D). These data indicate that ADP and phloxine B have distinct effects on the gating kinetics of CFTR. The ADP-induced decrease in beta 1 reduces the frequency with which CFTR channels enter the bursting state, whereas all the changes in rate constants produced by phloxine B prolong the duration of the bursting state. Because the effects of ADP and phloxine B on the rate constants oppose each other, Po in the presence of ADP and phloxine B did not differ from that of the control (Fig. 5B).


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 5.   Phloxine B (1 µM) relieves ADP inhibition of CFTR. A, representative recordings show the effect of phloxine B (1 µM) on the activity of two CFTR Cl- channels inhibited by ADP (0. 3 mM). B, effect of ADP (0.3 mM) and phloxine B (1 µM) on Po. Columns and error bars indicate means + S.E. (n = 5). The asterisk indicates a value that is significantly different from the control value (p < 0.05). C, a linear three-state model of CFTR channel gating (see Fig. 3A and Ref. 34). D, effect of ADP (0.3 mM) and phloxine B (1 µM) on the rate constants determined by the maximum likelihood fit to the model shown in C. Data are from four patches containing between one and four active channels. The asterisks indicate values that are significantly different from the control value (p < 0.05); other details are as in Fig. 2A.

Mechanism of Phloxine B Inhibition of CFTR-- Previous studies have demonstrated that some agents inhibit the CFTR Cl- channel by occluding the channel pore (19, 36, 37), whereas others interfere with channel gating (13, 31, 34). To investigate how phloxine B inhibits CFTR, we tested the effect of elevated concentrations of phloxine B on the single-channel activity of CFTR (Fig. 6A). Visual inspection of single-channel records suggests that phloxine B (20 µM) altered channel gating in several ways. First, it greatly prolonged the interburst interval (Fig. 6A). Second, it caused a large increase in flickery closures interrupting bursts of channel activity (Fig. 6A). Third, it appeared to prolong the duration of bursts (Fig. 6A). To begin to quantify channel block, we measured i and Po. Fig. 6 (B and C) demonstrates that phloxine B (20 µM) significantly decreased both i and Po (p < 0.05).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 6.   Elevated concentrations of phloxine B inhibit CFTR Cl- channels. A, representative recordings show the effect of phloxine B (20 µM) on the activity of three CFTR Cl- channels. The 1-s portions of trace indicated by the bars on the left are shown on an expanded time scale to the right. B and C, effect of phloxine B on i and Po, respectively. Columns and error bars indicate means + S.E. (n = 6). The asterisks indicate values that are significantly different from the control value (p < 0.05). Other details are as in Fig. 2A.

Fluorescein derivatives inhibit glibenclamide binding to SUR (25, 26). Based on these data, we were interested to learn the effect of phloxine B on glibenclamide inhibition of CFTR. Stimulation of CFTR with phloxine B (1 µM) failed to prevent channel block by glibenclamide (50 µM, n = 5, data not shown). Moreover, in the presence of glibenclamide (50 µM) and phloxine B (20 µM) channel inhibition was greater than that observed in the presence of either drug alone (p < 0.001, Fig. 7A and B (31)). These data suggest that glibenclamide and phloxine B might interact with CFTR at distinct sites.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of glibenclamide and ATP on phloxine B inhibition of CFTR. A, time-course of CFTR Cl- current in an excised inside-out membrane patch. ATP (0.3 mM), PKA (75 nM), phloxine B (20 µM), and glibenclamide (Glib, 50 µM) were present in the intracellular solution during the times indicated by the filled bars. Other details as in Fig. 1B. B, effect of glibenclamide (50 µM) on phloxine B (20 µM) inhibition of CFTR Cl- current. Columns and error bars indicate means + S.E. (n = 5). Values represent the average current recorded during the indicated interventions normalized to that measured under control conditions at the start of the experiment. Other details as in A. C, time-course of CFTR Cl- current in an excised inside-out membrane patch. ATP (0.3 or 5 mM), PKA (75 nM), and phloxine B (20 µM) were present in the intracellular solution during the times indicated by the filled bars. D, effect of ATP concentration on phloxine B (20 µM) inhibition of CFTR Cl- currents. Columns and error bars indicate means + S.E. (n = 6). Other details are as in B and C.

Elevated concentrations of the CFTR activator genistein inhibit channel activity by slowing greatly the rate of channel opening (13, 31). Like genistein, phloxine B prolonged the duration of long closures separating channel openings. This suggests that genistein and phloxine B might inhibit the CFTR Cl- channel by similar mechanisms. To test this idea, we investigated whether high concentrations of ATP attenuate phloxine B inhibition of CFTR. In contrast to genistein block of the CFTR Cl- channel (31), ATP (5 mM) failed to relieve phloxine B (20 µM) inhibition of CFTR Cl- currents (p > 0.05, Fig. 7, C and D).

The prolonged channel openings interrupted by flickery closures induced by inhibitory concentrations of phloxine B (Fig. 6A) suggest that phloxine B might be an open-channel blocker of CFTR. To investigate this idea, we examined the voltage dependence of channel inhibition. Membrane patches were bathed in symmetrical 147 mM Cl- solutions, and CFTR Cl- currents were recorded in the absence and presence of phloxine B (40 µM) over the voltage range ±100 mV using a voltage ramp protocol. Consistent with previous data (31), under control conditions, CFTR Cl- currents exhibited weak inward rectification (Fig. 8A). This rectification of CFTR is caused by a reduction in i and changes in gating behavior at voltages above +50 mV (38).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 8.   Phloxine B inhibition of CFTR is voltage-dependent and enhanced when the external Cl- concentration is reduced. A, I-V relationships of CFTR Cl- currents recorded in the absence and presence of phloxine B (40 µM) when the membrane patch was bathed in symmetrical 147 mM Cl- solutions. ATP (1 mM) and PKA (75 nM) were continuously present in the intracellular solution; holding voltage was -50 mV. B, effect of voltage on the fraction of CFTR Cl- current inhibited by phloxine B (40 µM). Values are means ± S.E. (n = 5) at each voltage. The continuous line is the fit of a second-order regression to the data. C, relationship between the voltage-dependent dissociation constant (Kd) and voltage when the external Cl- concentration was either 147 mM (filled circles) or 10 mM (open circles). Data are means ± S.E. (n = 4-5) at each voltage. The continuous lines are the fits of first-order regressions to the data.

Fig. 8A demonstrates that phloxine B inhibition of CFTR is voltage-dependent. Phloxine B (40 µM) decreased CFTR Cl- currents at negative voltages. However, at positive voltages inhibition was relieved. Using current values recorded in the presence and absence of phloxine B, we calculated the voltage-dependent dissociation constant (Kd) for phloxine B inhibition of CFTR from the equation,
K<SUB>d</SUB>(V)=[<UP>drug</UP>](I/I<SUB><UP>o</UP></SUB>−I) (Eq. 3)
where Kd(V) is the voltage-dependent dissociation constant at voltage V, and I and Io are the current values in the presence and absence of drug, respectively. Fig. 8C demonstrates that Kd values showed weak voltage dependence at negative voltages. However, at positive voltages Kd values were strongly voltage-dependent. The data also suggest that the potency of phloxine B inhibition of CFTR is comparable to glibenclamide and greater than that of genistein (phloxine B, Kd(0 mV) = 49 ± 7 µM (n = 5); glibenclamide, Kd(0 mV) = 37 ± 6 µM (19); genistein, Kd(0 mV) = 87 ± 11 µM (31)).

The electrical distance across the membrane sensed by blocking ions can be calculated using the Woodhull relationship (39),
K<SUB>d</SUB>(V)=K<SUB>d</SUB>(0 <UP>mV</UP>)<UP>exp</UP>[(<UP>−</UP>z′FV)/(RT)] (Eq. 4)
where z' is the apparent valency of the blocking ion (defined as the actual valency of the blocking ion (z) multiplied by the electrical distance across the membrane experienced by the blocking ion (delta )), and F, R, and T are the Faraday constant, gas constant, and absolute temperature, respectively. Using the data in Fig. 8C, z' = 0.04 ± 0.01 (n = 5) measured from the inside of the membrane over the voltage range -100 to -40 mV.

Because phloxine B inhibition of CFTR was voltage-dependent and unaffected by elevated ATP concentrations, we speculated that phloxine B might bind within the CFTR pore. To test this hypothesis, we reduced the external Cl- concentration to 10 mM and recorded CFTR Cl- currents in the absence and presence of phloxine B (40 µM) over the voltage range -100 to 0 mV using a voltage ramp protocol. Fig. 8C demonstrates that reducing the external Cl- concentration enhances the potency of phloxine B inhibition of CFTR (external [Cl-] = 147 mM, Kd(0 mV) = 49 ± 7 µM (n = 5); external [Cl-] = 10 mM, Kd(0 mV) = 26 ± 5 µM (n = 4); p < 0.05). However, reducing the external Cl- concentration was without effect on the electrical distance sensed by phloxine B (z' = 0.06 ± 0.01 (n = 4) measured from the inside of the membrane over the voltage range -100 to -40 mV; p > 0.05). Thus, these data indicate that phloxine B inhibition of CFTR is voltage-dependent and enhanced when the external Cl- concentration is reduced. This suggests that phloxine B might inhibit CFTR by occluding the CFTR pore.

Phloxine B Stimulates the CF-associated Mutant Delta F508 CFTR-- To begin to evaluate the therapeutic potential of phloxine B, we investigated whether phloxine B (1 µM) stimulates the activity of Delta F508 CFTR, the most common CF-associated mutant. Delta F508 CFTR causes a loss of Cl- channel function in two ways: first, it disrupts the biosynthesis of CFTR and second, it perturbs channel gating (12, 40). To investigate whether phloxine B stimulates the activity of Delta F508 CFTR Cl- channels, we grew cells at 28 °C to overcome the defective processing of Delta F508 CFTR and facilitate its delivery to the cell membrane (29). Fig. 9A shows the effect of phloxine B (1 µM) on the activity of a single Delta F508 CFTR Cl- channel following phosphorylation by PKA. Delta F508 CFTR Cl- channels are characterized by dramatically prolonged closures separating bursts of channel openings. As a result, the Po of Delta F508 CFTR is much less than that of wild-type CFTR (Figs. 2 and 9). Phloxine B (1 µM) increased the Po of Delta F508 CFTR 1.5-fold by enhancing burst duration (p < 0.05) without altering the interburst interval (p > 0.05, Fig. 9). These data demonstrate that phloxine B (1 µM) stimulates Delta F508 CFTR Cl- channels.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 9.   Phloxine B (1 µM) stimulates the single-channel activity of the CF-associated mutant Delta F508. A, representative recordings show the effect of phloxine B (1 µM) on the activity of a single Delta F508 CFTR Cl- channel. ATP (1 mM) and PKA (75 nM) were continuously present in the intracellular solution. B, C, and D, effect of phloxine B (1 µM) on Po, mean burst duration, and interburst interval. Columns and error bars indicate means + S.E. (n = 3-5). The asterisks indicate values that are significantly different from the control value (p < 0.05). Other details as in Fig. 2A.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The fluorescein derivative phloxine B is a potent modulator of CFTR with complex effects on channel activity. Low micromolar concentrations of phloxine B stimulate CFTR by prolonging channel openings. In contrast, higher concentrations of the drug inhibit CFTR by impeding Cl- permeation.

Activators of CFTR enhance channel activity either by regulating the intracellular signaling pathways that control CFTR activity or interacting directly with CFTR (8, 10). Several lines of evidence suggest that phloxine B acts by the latter mechanism. First, PKA and ATP were required for channel stimulation (27, present study). This indicates that cAMP-dependent phosphorylation of CFTR is a prerequisite for phloxine B to augment channel activity. Second, phloxine B enhanced channel activity in excised inside-out membrane patches (27, present study). This suggests that phloxine B might bind directly to CFTR. Third, phloxine B stimulated channel activity by prolonging the duration of channel openings (present study). Based on previous work (for review see Ref. 2), this result suggests that phloxine B might inhibit channel closure. These characteristics of phloxine B stimulation of CFTR resemble those of genistein, a CFTR activator that interacts directly with CFTR (11-14, 41). However, they differ markedly from those of bromotetramisole, a CFTR activator that inhibits protein phosphatases (9). Consistent with these data, phloxine B (1 µM) and bromotetramisole (3 mM) stimulation of CFTR Cl- currents was additive (n = 4, data not shown).

Al-Nakkash et al. (42) proposed that genistein and benzimidazolones stimulate CFTR by a common mechanism. These drugs inhibit ATP hydrolysis at NBD2 to stabilize the open channel configuration. Our observation that phloxine B inhibits channel closure suggests that phloxine B might stimulate CFTR by a similar mechanism. However, the observation that phloxine B, but not genistein, altered the relationship between ATP concentration and channel activity (13, 27, 43, present study) argues that phloxine B stimulates CFTR by a distinct mechanism. Given that fluorescein derivatives inhibit ATP hydrolysis by transport ATPases (23, 24), that CFTR possesses two NBDs that bind and hydrolysis ATP (44), and that phloxine B enhances the affinity of CFTR for ATP (27, present study), we speculate that phloxine B stimulates CFTR by interacting with the NBDs.

A variety of models have been proposed to account for the regulation of channel gating by the NBDs (for discussion see Ref. 45). In the model of Zeltwanger et al. (46), brief channel openings in the presence of low ATP concentrations reflect ATP binding and hydrolysis at NBD1, whereas prolonged channel openings in the presence of high ATP concentrations reflect ATP binding and hydrolysis at NBD2. To explain how phloxine B stimulates CFTR, we propose that phloxine B binding to one NBD (we suggest NBD2) slows the rate of ATP dissociation at NBD1. Consistent with our data, this interpretation predicts that phloxine B would increase burst duration without altering the interburst interval.

Fluorescein derivatives interact with several sites on transport ATPases, with the principal site being the high affinity ATP-binding site of the catalytic subunit (23). These data suggest that phloxine B might prevent ATP dissociation from NBD1 by binding at the ATP-binding site of NBD2. This interpretation predicts that phloxine B and ATP compete for a common binding site on NBD2. To test this idea, we used phloxine (1 µM), whereas Bachmann et al. (27) used phloxine B (300 nM). Because competition was only observed using phloxine B (300 nM (27)), phloxine B and ATP might only compete for a common binding site at non-saturating (nanomolar) concentrations of the drug. At saturating (micromolar) concentrations of the drug, phloxine B might interact with a site distinct from the ATP-binding site. Given that fluorescein derivatives are hydrophobic analogues of AMP (24) and AMP interacts with a site distinct from that of ATP to enhance the affinity of NBD2 for ATP (14), we speculate that high concentrations of phloxine B might stimulate CFTR by binding at or near the AMP-binding site of NBD2.

Like genistein (13, 31), elevated concentrations of phloxine B inhibit the CFTR Cl- channel. Both genistein and phloxine B caused a flickery block that prolonged the duration of bursts and lengthened dramatically the interburst interval (31, present study). However, ATP (5 mM), voltage, and Cl- concentration had markedly different effects on channel block by these agents (31, present study). Genistein inhibition was voltage-independent, unaffected by reducing the external Cl- concentration, and relieved by ATP (5 mM (31)). In contrast, phloxine B inhibition was voltage-dependent, enhanced when the external Cl- concentration was reduced, and unaffected by ATP (5 mM, present study). The failure of ATP (5 mM) to relieve phloxine B inhibition of CFTR was not a consequence of the slow dissociation of the drug from the channel.3

Previous work has demonstrated that large anions cause a voltage-dependent block of the CFTR Cl- channel by binding to sites located 15-60% of the way through the transmembrane electric field from the inside (19, 22, 36, 37, 47-49). In contrast, the phloxine B-binding site is located only 4% of the way through the transmembrane electric field from the inside. This suggests that phloxine B interacts with a site outside the pore to block CFTR. For two reasons, we do not favor this interpretation. First, phloxine B inhibition of CFTR was voltage-dependent and enhanced when the external Cl- concentration was reduced. These data suggest strongly that phloxine B enters the CFTR pore from the intracellular end, binds at or near Cl--binding sites, and blocks Cl- flow. Second, calculation of the electrical distance that is sensed by phloxine B is complex. The Hill coefficient for phloxine B inhibition of CFTR is 2. This suggests that phloxine B might block the CFTR Cl- channel by binding to two or more sites. Consistent with this idea, phloxine B possesses two negative charges located on different parts of the molecule (Fig. 1A). This suggests that these charges might experience different fractions of the transmembrane electric field when phloxine B inhibits CFTR. However, the relationship between electrical distance and physical distance within the CFTR pore is unknown. Based on our experience with genistein (31), it is feasible that phloxine B might bind to a site deep within the CFTR pore. Alternatively, the drug might interact with a site at the extremity of the intracellular vestibule. Given the location of the glibenclamide-binding site (19, 50) and our observation that channel block by phloxine B and glibenclamide was additive, we favor this possibility.

In conclusion, our data indicate that phloxine B is a potent modulator of the CFTR Cl- channel. They also suggest that phloxine B interacts directly with CFTR at multiple sites to modulate channel activity. Based on the present results, future studies might identify the phloxine B-binding sites.

    ACKNOWLEDGEMENTS

We thank Professors D. C. Gadsby, S. L. Flitsch, and M. J. Welsh and our departmental colleagues for valuable discussions and Dr. C. R. O'Riordan (Genzyme) and Professor M. J. Welsh (University of Iowa) for the generous gift of C127 cells.

    FOOTNOTES

* This work was supported by the Biotechnology and Biological Sciences Research Council, Cystic Fibrosis Trust, and the National Kidney Research Fund.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at www.jbc.org) contains Tables 1-3.

Dagger To whom correspondence should be addressed: Dept. of Physiology, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, United Kingdom. Tel.: 44-117-928-8992; Fax: 44-117-928-8923; E-mail: D.N.Sheppard@bristol.ac.uk.

Published, JBC Papers in Press, March 19, 2002, DOI 10.1074/jbc.M108023200

2 Similar results were observed using a tc of 80 ms (n = 6).

3 We observed identical effects of ATP (5 mM) using eosin Y, a fluorescein derivative closely related to phloxine B. Eosin Y and phloxine B stimulate and inhibit CFTR Cl- currents with similar potency (n = 29, Z. Cai and D. N. Sheppard, unpublished observation). However, channel block by eosin Y is readily reversible (n = 5, data not shown) compared with that of phloxine B.

    ABBREVIATIONS

The abbreviations used are: CFTR, cystic fibrosis transmembrane conductance regulator; CF, cystic fibrosis; ABC, ATP-binding cassette; AMP-PNP, adenosine 5'-(beta ,gamma -imino)triphosphate; ADPKD, autosomal dominant polycystic kidney disease; i, single-channel current amplitude; I-V, current-voltage; KATP channel, ATP-sensitive K+ channel; MRP, multidrug-resistance associated protein; NBD, nucleotide-binding domain; NMDG, N-methyl-D-glucamine; PKA, protein kinase A; Po, open probability; R domain, regulatory domain; SUR, sulfonylurea receptor; TES, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., Drumm, M. L., Iannuzzi, M. C., Collins, F. S., and Tsui, L.-C. (1989) Science 245, 1066-1073[Abstract/Free Full Text]
2. Gadsby, D. C., and Nairn, A. C. (1999) Physiol. Rev. 79, S77-S107[Medline] [Order article via Infotrieve]
3. Sheppard, D. N., and Welsh, M. J. (1999) Physiol. Rev. 79, S23-S45[Medline] [Order article via Infotrieve]
4. Welsh, M. J., Tsui, L.-C., Boat, T. F., and Beaudet, A. L. (1995) in The Metabolic and Molecular Basis of Inherited Disease (Scriver, C. R. , Beaudet, A. L. , Sly, W. S. , and Valle, D., eds) , pp. 3799-3876, McGraw-Hill Inc., New York
5. Sullivan, L. P., Wallace, D. P., and Grantham, J. J. (1998) Physiol. Rev. 78, 1165-1191[Abstract/Free Full Text]
6. Gabriel, S. E., Brigman, K. N., Koller, B. H., Boucher, R. C., and Stutts, M. J. (1994) Science 266, 107-109[Abstract/Free Full Text]
7. Guerrant, R. L., Hughes, J. M., Lima, N. L., and Crane, J. (1990) Rev. Infect. Dis. 12, S41-S50[Medline] [Order article via Infotrieve]
8. Schultz, B. D., Singh, A. K., Devor, D. C., and Bridges, R. J. (1999) Physiol. Rev. 79, S109-S144[Medline] [Order article via Infotrieve]
9. Luo, J., Zhu, T., Evagelidis, A., Pato, M. D., and Hanrahan, J. W. (2000) Am. J. Physiol. 279, C108-C119
10. Hwang, T.-C., and Sheppard, D. N. (1999) Trends Pharmacol. Sci. 20, 448-453[CrossRef][Medline] [Order article via Infotrieve]
11. French, P. J., Bijman, J., Bot, A. G., Boomaars, W. E. M., Scholte, B. J., and de Jonge, H. R. (1997) Am. J. Physiol. 273, C747-C753[Medline] [Order article via Infotrieve]
12. Hwang, T.-C., Wang, F., Yang, I. C.-H., and Reenstra, W. W. (1997) Am. J. Physiol. 273, C988-C998[Medline] [Order article via Infotrieve]
13. Wang, F., Zeltwanger, S., Yang, I. C.-H., Nairn, A. C., and Hwang, T.-C. (1998) J. Gen. Physiol. 111, 477-490[Abstract/Free Full Text]
14. Randak, C., Auerswald, E. A., Assfalg-Machleidt, I., Reenstra, W. W., and Machleidt, W. (1999) Biochem. J. 340, 227-235[CrossRef][Medline] [Order article via Infotrieve]
15. Xie, J., Zhao, J., Davis, P. B., and Ma, J. (2000) Biophys. J. 78, 1293-1305[Abstract/Free Full Text]
16. Dean, M., Rzhetsky, A., and Allikmets, R. (2001) Genome Res. 11, 1156-1166[Abstract/Free Full Text]
17. Inagaki, N., Gonoi, T., Clement IV, J. P., Namba, N., Inazawa, J., Gonzalez, G., Aguilar-Bryan, L., Seino, S., and Bryan, J. (1995) Science 270, 1166-1170[Abstract/Free Full Text]
18. Venglarik, C. J., Schultz, B. D., DeRoos, A. D. G., Singh, A. K., and Bridges, R. J. (1996) Biophys. J. 70, 2696-2703[Abstract/Free Full Text]
19. Sheppard, D. N., and Robinson, K. A. (1997) J. Physiol. 503, 333-346[Abstract/Free Full Text]
20. Cai, Z., Lansdell, K. A., and Sheppard, D. N. (1999) Br. J. Pharmacol. 128, 108-118[CrossRef][Medline] [Order article via Infotrieve]
21. Oude Elferink, R. P. J., and Groen, A. K. (2000) Semin. Liver Dis. 20, 293-305[CrossRef][Medline] [Order article via Infotrieve]
22. Linsdell, P., and Hanrahan, J. W. (1999) Br. J. Pharmacol. 126, 1471-1477[CrossRef][Medline] [Order article via Infotrieve]
23. Karlish, S. J. D. (1980) J. Bioenerg. Biomembr. 12, 111-136[CrossRef][Medline] [Order article via Infotrieve]
24. Neslund, G. G., Miara, J. E., Kang, J.-J., and Dahms, A. S. (1984) Curr. Top. Cell Regul. 24, 447-469[Medline] [Order article via Infotrieve]
25. de Weille, J. R., Müller, M., and Lazdunski, M. (1992) J. Biol. Chem. 267, 4557-4563[Abstract/Free Full Text]
26. Schwanstecher, M., Bachmann, C., Löser, S., and Panten, U. (1995) Pharmacology 50, 182-191[Medline] [Order article via Infotrieve]
27. Bachmann, A., Russ, U., Waldegger, S., and Quast, U. (2000) Br. J. Pharmacol. 131, 433-440[CrossRef][Medline] [Order article via Infotrieve]
28. Marshall, J., Fang, S., Ostedgaard, L. S., O'Riordan, C. R., Ferrara, D., Amara, J. F., Hoppe IV, H., Scheule, R. K., Welsh, M. J., Smith, A. E., and Cheng, S. H. (1994) J. Biol. Chem. 269, 2987-2995[Abstract/Free Full Text]
29. Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., and Welsh, M. J. (1992) Nature 358, 761-764[CrossRef][Medline] [Order article via Infotrieve]
30. Hamill, O. P., Marty, A., Neher, E., Sakmann, B., and Sigworth, F. J. (1981) Pflügers Arch. 391, 85-100[CrossRef][Medline]